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Abstract This report contains selected excerpts,
presented as a summary, from a public workshop
sponsored by the American Association of Tissue
Banks (AATB) held to discuss West Nile Virus
(WNV) and scientific considerations for tissue donors.
The daylong workshop was held 9 July 2010 at the
Ritz-Carlton Hotel at Tyson’s Corner in McLean,
Virginia, United States (U.S.). The workshop was
designed to determine and discuss scientific informa-
tion that is known, and what is not known, regarding
WNV infection and transmission. The goal is to
determine how to fill gaps in knowledge of WNV and
tissue donation and transplantation by pursuing rele-
vant scientific studies. This information should ulti-
mately support decisions leading to appropriate tissue
donor screening and testing considerations. Discus-
sion topics were related to identifying these gaps and
determining possible solutions. Workshop participants
included subject-matter experts from the U.S. Food
and Drug Administration, the Centers for Disease
Control and Prevention, U.S. Department of Health
and Human Services, Health Canada, the Public
Health Agency of Canada, AATB-accredited tissue
banks including reproductive tissue banks, accredited
eye banks of the Eye Bank Association of America,
testing laboratories, and infectious disease and organ
transplantation professionals. After all presentations
concluded, a panel addressed this question: ‘‘What are
the scientific considerations for tissue donors and what
research could be performed to address those consid-
erations?’’ The slide presentations from the workshop
are available at: http://www.aatb.org/2010-West-Nile-
Virus-Workshop-Presentations.
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Opening remarks
P. Robert Rigney, Jr., Esq.
Chief Executive Officer, AATB
Bob Rigney opened the workshop by welcoming
attendees to this ‘‘critically important meeting.’’ He
briefly reviewed the history of the Food and Drug
Administration’s (FDA’s) proposed rulemaking on
West Nile Virus (WNV) testing and the AATB’s
response that produced this workshop. He also
thanked the various offices within FDA and the
Centers for Disease Control and Prevention (CDC)
for their assistance in developing the workshop. Mr.
Rigney highlighted that the principal goal for the
workshop was ‘‘to evaluate what is known about
WNV, and what studies might need to be done to
assess the value of WNV testing of tissue donors. We
believe an outcome of this workshop will be to pursue
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scientific studies that adequately characterize WNV,
and that will support any final decision made regarding
tissue donor testing for WNV.’’
FDA and regulation of human cells, tissues,
and cellular- and tissue-based products
Melissa Greenwald, MD
Chief of the Reproductive and Human Tissue Branch,
Division of Human Tissues
Office of Cellular, Tissue and Gene Therapies; Center
for Biologics Evaluation and Research (CBER), FDA
The FDA works with manufacturers and sponsors who
develop tests using post-mortem blood specimens
(also known as post-asystole blood specimens). There
is a requirement for validation studies for post-
asystole specimens that are separate from a blood
donor screening indication, in part because there has
been concern about interfering substances that could
prevent the detection of targeted analytes.
‘‘We require additional validation studies in order
for the test kit manufacturers to add an indication for
use in testing donors whose blood as been collected
post-asystole,’’ said Dr. Melissa Greenwald. ‘‘So far,
all licensed tests that have this donor-screening
indication have been validated in tests developed for
use in blood donors.’’
The 2004 guidelines for obtaining the post-asystole
indication for use are predicated on obtaining a blood
donor screening claim. The data can be submitted for
the claim either submitting a biologics license appli-
cation, or, if one already has a blood donor claim, one
can submit a supplement to FDA any time after the test
is licensed.
Sensitivity, specificity, and reproducibility studies
are required to meet minimal study requirements for a
post-asystole specimen claim.
‘‘It is difficult to collect matched pre- and post-
mortem specimens. So far, everybody that has come to
us that has obtained a license to test cadaveric donor
specimens has done the unmatched specimen studies,’’
Dr. Greenwald said.
Spiking studies are acceptable for the sensitivity
and reproducibility studies—studies where an analyte
needs to be present.
Sensitivity and specificity studies require a mini-
mum of 50 specimens; reproducibility studies require
20. Manufacturers or sponsors must use a minimum of
three test kit lots per study. They must collect
additional information about the donors, such as the
time of death and when, how, and where the specimen
was collected. The degree of hemolysis should also be
documented, along with information about storage and
handling.
It was described that in order for the sponsor to
provide information in the manufacturer’s instructions
for use concerning how long you can store the
specimen, the types of tubes to use, or shipping and
storage requirements, the sponsor must provide data to
substantiate these additional instructions.
Laboratory studies demonstrate that a product
meets requirements for safety, purity, and potency.
Examples include assay precision, lab proficiency,
analytical sensitivity and specificity, chemistry, man-
ufacturing, and controls.
Clinical evaluation studies demonstrate the safety
and efficacy for a specific intended use. Examples
include clinical sensitivity and specificity, reproduc-
ibility, and stability.
Analytical specificity measures a test’s ability to
exclusively identify a target substance rather than
different substances. Studies evaluating analytical
specificity may look at interfering substances, viral
infections, common disease conditions that could
yield false positives, and to compare signal strength
between pre- and post-asystole to ensure an assay is
working.
Clinical sensitivity is a measure of how often a test
is positive in diseased donors. It is evaluated by
specimens from seroconverting individuals. The fre-
quency of false positive test results are compared for
pre- and post-asystole specimens. Theoretically they
should have the same amount of analyte in them, but
the signals will differ based on how the assays are
performing.
‘‘It’s the clinical sensitivity that’s probably the
weakest in the way the tests are currently evaluated,
because of the spiking studies’’ Dr. Greenwald said.
Assay precision measures the closeness of agree-
ment between a series of measurements obtained from
multiple sampling of the homogeneous sample under
the prescribed conditions.
Reproducibility is a particular measure of assay
precision, specifically the precision of measurements
obtained when the test is performed in different
laboratories. Reproducibility studies include testing
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across multiple operators, lots, and days, at different
sites. Twenty specimens are required; each specimen
must be tested on six different days, by six different
operators, across three different lots.
Dr. Greenwald highlighted the following knowl-
edge limitations:
• When small numbers of specimens are involved,
confidence intervals will be large, so specificities
estimations are not precise.
• Spiking studies are done to evaluate sensitivity, but
for post-asystole specimens the sensitivity studies
are really designed to exclude major differences in
or problems with the ability of the test to detect a
target analyte as compared to blood donor spec-
imens where the test has been well characterized,
rather than to stand-alone in characterizing the
sensitivity of the assay.
• Sometimes the options, such as the type of
specimen tubes, the shipping time, or storage time,
are more limited for post-asystole specimens. For
example, EDTA (ethylene diamine tetraacetic
acid) plasma tubes are typically validated by the
sponsor, but other tube types rarely are evaluated.
• Until recently, sponsors have not studied how well
a test performs after specimens have been frozen
for a few months. Sponsors have been more
frequently willing to validate longer storage claims
of late.
She briefly described a sensitivity study currently
underway comparing the test results from specimens
obtained from deceased individuals who have HIV,
hepatitis B virus, or hepatitis C virus. She also
described a proposed specificity study to compare
the specificity of donor screening tests currently
licensed for post asystole specimens by comparing
pre- and post-asystole specimens obtained from the
same individuals and tested across all currently
licensed tests. That study protocol is currently in the
planning stages.
‘‘We’re trying to balance the availability of infor-
mation about how these specimens perform, and the
volume of information, because if we ask for too
much, we might get nothing. There’s room for
improvement on the amount of information we’d like
to see, and we’re evaluating this as time goes on,’’
Dr. Greenwald said. She noted that many opportunities
exist for increased data collection or review to inform
donor screening and testing policy.
‘‘That’s why we are here today,’’ she said. ‘‘We are
interested in opportunities to better inform regulatory
review. The FDA will always review policy decisions
in light of new or better data, once collected.’’
The tissue safety lab at the CBER is up and running,
and ideas for studies are welcome.
Overview of West Nile Virus
Mike Drebot, PhD
Chief, Viral Zoonoses & Research Coordination:
H1N1 Studies
Director, Science Technology and Core Services,
National Microbiology Laboratory
Public Health Agency of Canada
WNV is a member of the flavivirus genus which
consists of more than 70 members of which half are
associated with human disease, said Dr. Mike Drebot.
The virus is a mosquito-borne virus and a member of
the Japanese encephalitis serocomplex. Dr. Robert
Lanciotti (CDC) has characterized two main lineages:
lineage 2 from Sub-Saharan Africa, and lineage 1
associated with southern Africa, Europe, and North
America.
The North American strain of WNV has not
changed much, he said; however, there is evidence
that the 1999 virus may have evolved to be more
efficiently transmitted by mosquitoes.
The 3-‘non-translated region of the WNV genome
is important for viral replication, however, mutants
with 100 nucleotide deletions in this region of the
genome have been found. ‘‘Dr. Maria Rios identified
some of these and we have been working with Maria to
try to document their prevalence and whether these are
taking up more of a niche,’’ said Dr. Drebot. ‘‘In
Canada, we have found them not only in field
specimens (birds, mosquito isolates), but also in
infected blood donors.’’ The Public Health Agency
of Canada (PHAC) continues to monitor this, in
collaboration with Dr. Rios and others.
Most cases of WNV occur via mosquito inocula-
tion. The virus enters by endocytosis and uncoats. The
first round of replication occurs within the skin, where
dendritic cells migrate to the lymph nodes. A second
round produces viremia and systematic spread to
various degrees, with the kidney and spleen being
prominent. Rarely, infection of the central nervous
system occurs.
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The incubation period is 2–15 days after exposure,
followed by a transient viremia for about 1 week.
‘‘For the most part, you can be viremic and have no
antibody response, and you can also be viremic and
not show any symptoms,’’ Dr. Drebot said, noting that
80% or more individuals are asymptomatic. Some are
at higher risk due to age, underlying medical condi-
tions, and a host of genetic factors.
Since WNV contains non-structural proteins that
interfere with interferon, it can counteract immune
responses, as well as interfering with the complement
pathway, Dr. Drebot said.
J. Erin Staples, MD, PhD
Medical Epidemiologist, CDC
Fort Collins, Colorado
WNV infections in humans are asymptomatic in most
or 80% of persons. However, 20% of those who are
infected will develop a non-specific febrile illness and
less than 1% will develop more severe neuroinvasive
disease. Recent blood donor data show that 42% of
individuals infected with WNV will have symptoms.
Approximately 25% will report a rash, weakness, or
headache, and close to 15% will report a fever. Less
than 1% will develop neuroinvasive disease such as
encephalitis, meningitis, or acute flaccid paralysis.
Overall, approximately 4% of WNV cases are fatal.
ArboNET is the national arboviral surveillance
system in the United States. It is an electronic system
developed by the CDC in response to the WNV. It is
unique in that it combines human and non-human data.
It can readily adapt to new modes of transmission.
Since 2002 the number of dead birds in the United
States has gradually declined, while the mosquito
population has remained stable at relatively low levels.
The CDC recently published a 10-year summary of
WNV activity. During this period approximately
29,000 cases were reported from 1,800 counties in
47 states and the District of Columbia. Maine, Alaska,
and Hawaii have had no human cases, while Maine has
reported non-human activity.
It is thought that West Nile fever is significantly
under-reported. Close to 1.7 million individuals were
infected in the United States over the 10-year period,
according to serostudies. ‘‘If 19% of those result in
fever, then we should have seen over 300,000 cases of
West Nile fever, but we’ve seen less than 5% of that.
Neuroinvasive disease is a better indicator of the
epidemiology of the disease,’’ Dr. Staples said.
The disease was established on the east coast for
the first 3 years, before expanding across the country.
A steady state was reached between 2004 and 2007,
followed by declines in 2008 and 2009. It is not
possible to predict the incidence from 1 year to the
next. The north-central plains states and the Louisiana-
Mississippi region are hot spots.
ArboNET data show human cases of WNV with
onset reported between January 2 and December 31,
but approximately 90% are reported between July and
September.
Epidemiology in Canada (Mike Drebot, PhD)
A total of 4,500 cases of WNV have been documented
in Canada, with British Columbia seeing its first case
in 2009.
Bird testing in Canada began in 2001. Southern
Ontario saw the first bird cases in 2001, and by 2002
nearly 1,000 human cases were reported in Ontario
and Quebec. In 2003 the virus swept into western
Canada. A drop in 2004 was caused by a cold summer,
but the hot summer of 2007 brought high levels of
activity. The mid-western provinces of Manitoba,
Saskatchewan, and Alberta are hot spots in Canada.
‘‘A recent study found evidence of shedding of the
viral RNA in urine 6 years after a group of individuals
in Houston showed encephalitis,’’ said Dr. Drebot.
‘‘So persistence of the virus is something to keep on
the radar.’’
Discussion
A participant asked whether the mosquito is initially
infected, and whether evidence shows the virus being
transmitted from an animal host back into an insect.
Dr. Drebot said that more than 100 species of birds
make up the main reservoir for WNV—even crows are
viremic and can infect mosquitoes. The virus can
persist if it is in the tissues of a dead bird, which are
eaten by scavengers.
Responding to a question about whether songbirds
carry WNV, Dr. Drebot said birds such as robins have
been documented as good amplifying hosts for the
virus.
‘‘What’s up with British Columbia?’’ a participant
asked, noting that while the vector is there, cases are
rare. ‘‘We ask this all the time about the states of
Washington and Maine,’’ the participant said. Noting
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that the virus needs heat to replicate effectively,
Dr. Drebot said, ‘‘I think the marine climates are not
conducive for good amplification of the virus.’’
Asked about addressing any pushback from
Canada’s blood community following years with no
cases, Dr. Drebot said, ‘‘We continue to test all blood
because the logistics and cost benefits are better when
testing is uninterrupted. However, this continues to be
revisited.’’ A participant commented that Health
Canada does not mandate year-round blood testing.
‘‘We have two blood systems: the Canadian blood
system and He´ma-Que´bec; and He´ma-Que´bec does
not do year-round testing.’’
Dr. Lyle Petersen commented that a study con-
ducted in the 1950s, when WNV was tried as a cancer
treatment, showed data on patients who died. At that
time, scientists were able to isolate the virus from
organs and tissues up to about 40 days after the
inoculation. This offers good evidence for persistence
in humans. ‘‘With respect to longer-term persistence,
we did a study in South Dakota looking at seroprev-
alence for WNV in blood donors, and found that WNV
antibody prevalence was about 8%.’’ With so many
people infected, if WNV did persist in organs,
transmission via that route would be much higher
than it is. ‘‘My guess is that the long-term persistence
issue is probably not that important other than for a
short period of a month or two,’’ Dr. Petersen said.
Dr. Drebot agreed, but asked whether Dr. Petersen
was talking about the persistence of viable virus. Some
evidence indicates that these viruses can integrate. ‘‘It
could be that what we are picking up is expression of
the virus, but not an infectious virus.’’
A participant asked panelists whether they thought
WNV prevalence would settle down, similar to eastern
equine encephalitis or Japanese encephalitis; if it does,
‘‘Why are we talking about preventing transmission
and tissue donors? Do we have to start testing for all
the other arboviruses out there?’’
Dr. Drebot said that in Canada, the intention is to
continue monitoring the virus, since viremia is more
pronounced in various amplifying hosts (e.g., birds)
for WNV than other arboviruses. Dr. Staples added
that it is impossible to predict where the disease will
occur each year. ‘‘It could be quiet for years and then
you see thousands of cases, so do we not want to be
screening when that happens? I do not know the
answer to that yet.’’
Asked about the challenges in collecting epidemi-
ological data on the numbers of infected humans each
year, Dr. Staples said the CDC and selected state
health departments are looking at under-diagnosis and
under-reporting.
Another participant asked whether the testes and
ovaries harbor the WNV; Dr. Staples said no one
has examined this question. The participant asked
whether it would be useful to provide Dr. Staples’
lab with human tissue samples for assessment;
Dr. Staples said this would definitely be a consider-
ation. Dr. Drebot added that this could become part of
a study design.
A participant asked the panel when they would feel
comfortable in saying the incidence of WNV is
declining. Dr. Staples said that due to all the biological
factors involved, ‘‘I do not think I will ever feel
comfortable with it.’’ Another participant agreed:
‘‘Five years does not make a trend. These are episodic
diseases.’’
Assessing risk of transmission through tissues:
a CDC perspective
Matt Kuehnert, MD
Director, Office of Blood, Organ and Other Tissue
Safety
CDC
‘‘Given that there are no reports of tissue-transmitted
WNV, we have to look at what we know about blood
and organ transmission,’’ said Dr. Matt Kuehnert.
‘‘Also, we can look at other viruses to give us
perspective on how WNV might behave.’’
The CDC does risk assessment through investiga-
tions, surveillance, statistical modeling, and research.
Investigations are prompted by invitations based on
word of possible transmissions; this information
comes from the FDA, the Health Resources and
Services Administration, the United Network for
Organ Sharing (which operates the Organ Procure-
ment and Transplantation Network), and an OPTN
disease transmission advisory committee that collects
cases related to organ transplantation. State health
departments, tissue banks, organ procurement organi-
zations (OPOs), clinicians, pathologists, laboratory
staff, and even patients and their families can provide
important clues about potential cases.
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Tissue allografts have a risk of disease transmis-
sion. Processing can mitigate risk; however, tech-
niques are not well standardized from tissue bank to
tissue bank and overall efficacy is not well defined. For
example, in one 1985 case, HIV was transmitted by
unprocessed frozen tendon and femoral heads, but not
transmitted by freeze-dried or irradiated products. In
another case, hepatitis C was transmitted to multiple
organ and tissue recipients, but only by tendon and
saphenous vein.
‘‘This case is important because it ties in
the relationship between organ and tissue,’’ said
Dr. Kuehnert. ‘‘Unfortunately, it was a lesson in
retrospect where the organ recipients were recog-
nized as having HCV infection but the tissue bank
was unaware and ended up releasing the infected
tissue.’’ This reinforces the importance of commu-
nication between OPOs and tissue banks as well as
of understanding risk.
Dr. Kuehnert addressed the importance of organ
donors that have transmitted WNV despite having
evidence of IgM and lacking evidence of viremia and
whether this reflects a persistent reservoir outside the
blood in some patients. A case in Louisiana involved
an organ transplant recipient who was infected, and
the organ donor had been transfused. The IgM and
nucleic acid testing (NAT) from serum/plasma were
both negative. The blood donation was implicated for
WNV, suggesting the organ donor as a conduit for
infection despite the lack of evidence by NAT.
‘‘Presumably there was a hemodilution effect to
explain those findings, but we can only propose that
as a hypothesis,’’ said Dr. Kuehnert.
The question of how viral loads and blood donors
are meaningful in terms of tissue type, and in terms of
processed tissue, is an important one. ‘‘We really have
to take them [each tissue type] case by case.’’
If the latency period for WNV is longer than
expected, it can affect adequate surveillance.
While reporting systems are in place for organ and
tissue safety, FDA HCT/P regulations extend only to
the hospital door, Dr. Kuehnert said. Tissue banks can
only report an adverse reaction if they know it
occurred, but if the clinicians do not report it, this
leaves a gap.
There are real issues with tissue surveillance.
Barriers to surveillance include lack of fundamental
solutions for traceability. First, tissue nomenclature is
not standardized.
Also donor identifiers are fragmented across the
system, so having a unique identifier would help
clinicians to link events. ‘‘A [surveillance] platform
hasn’t been developed, but AATB has been very
involved in trying to create the infrastructure to
facilitate this,’’ Dr. Kuehnert said. Denominator data
would be one benefit of having a working tissue
surveillance system. Research could feed into
surveillance.
The risk for transmission is unknown in most
tissues. Tissue characteristics should be taken into
context. For example, in a recent case of chronic Q
fever there was a question of the risk in blood and
tissues. While it was thought that the risk was small for
blood and most tissues, someone brought up bone
marrow transplantation.
‘‘When you think about [the potential transmission
risk of] heart valves and bone marrow, it is a different
story’’, Dr. Kuehnert said.
Much can be learned from the organ world with
respect to disease transmission, because the rates are
so much higher compared with blood and tissue.
‘‘After solid organs, I think we need to look at
minimally processed tissue in terms of the highest risk.
I think there would be minimized risk as tissue is more
heavily processed, but that needs to be shown.’’
Scaled risk assessment is the goal, given the
minimized risk in heavily processed tissue, and the
small number of minimally processed tissue that may
have greater risk: ‘‘We would like to be involved with
projects that focus on where we need to focus our
surveillance, and include certain groups of clinicians
that use those tissues at highest risk,’’ Dr. Kuehnert
said. ‘‘I am not sure that statistically you might expect
a WNV transmission in tissue. We haven’t done that
statistical modeling yet, but I think it could be useful.’’
Recipient demographics and risk considerations
Marian G. Michaels, MD, MPH
Professor of Pediatrics and Surgery, Division of
Infectious Diseases
Children’s Hospital of Pittsburgh
Clinical reporting is passive and relies on health care
workers thinking about the disease, being able to
diagnose it correctly, and reporting it consistently, said
Dr. Marian G. Michaels.
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ArboNET data show that risk for neuroinvasive
disease increases with age, although a study from
North Dakota showed the younger population to be at
highest risk for acquiring the disease. Immunosup-
pressed individuals are also at high risk for symptom-
atic disease.
‘‘If the decision is made not to have universal
screening, there will need to be good communication
with the blood banks,’’ Dr. Michaels said. ‘‘Since there
is no specific treatment the emphasis has to be aimed at
prevention.’’
Supportive care is the mainstay of treatment.
Immunoglobulin has been of interest as a potential
treatment due to the suggestion that prior immunity
should offer protection and anecdotal reports of the use
of high titer WNV specific IVIG seemed to offer
benefit. However, a randomized controlled trial of a
single dose of the high-titered WNV IVIG (0.5 mg/kg),
versus standard IVIG or placebo, failed to provide
clinical benefit in adults with symptomatic disease.
Further studies of different dosing schedules, or its use
for recipients of organs from a donor found to have
WNV, need to be investigated further.
Animal studies have shown that interferon alpha-2b
may improve survival, particularly with increasing
doses. Likewise, case reports suggest temporal improve-
ment. Looking at a non-controlled, single-center study
of the St. Louis flavivirus (another Arbovirus), 15
subjects received interferon and 17 did not; only two
of the 15 treated subjects had serious disease requiring
hospitalization of more than 1 week whereas 11 of the
17 untreated subjects had serious disease requiring
hospitalization of more than 1 week.
Hamster studies have shown that a humanized
monoclonal antibody currently in clinical trials has
potential, even after neurological symptoms have
developed.
Studies show that ribavirin is associated with worse
outcome and is therefore contraindicated.
Discussion
Noting, ‘‘We are good at coming up with national
policies, but not localized policies,’’ a participant
asked how to address issues that might be more
localized. For example, while it might not be appro-
priate to test a donor in Maine, testing might be
indicated in Colorado. ‘‘How do we become flexible in
our policies, and does the FDA have mechanisms to
address these issues?’’
Dr. Greenwald acknowledged that in terms of
policy, this is indeed challenging. Given that it is
impossible to predict where the concern will be at any
given time, ‘‘I do not have the answer as to how this
challenge can be addressed.’’
Another participant commented that Alaska is
visited all summer by thousands of tourists and big
ships from around the world. This illustrates the
difficulty of determining where an individual has spent
time before they are presented as a potential donor.
Noting that better communication is essential,
Dr. Greenwald said, ‘‘I think this is why it made sense
to go with universal testing from the blood bank side.’’
A participant commented that as an association,
those present should try to develop communication
between blood establishments, collection centers,
OPOs, and tissue banks. However, the participant said
it would be important to consider how this would fit
into the regulatory scheme and testing.
Experiences using WNV NAT
Jerry Niedzinski, BS, CHS
Senior Scientist
LABS, Inc.
Jerry Niedzinski compared the Procleix WNV test
(Novartis Diagnostics) that is based on transcription-
mediated amplification (TMA), with the Cobas Taq-
Screen MPX test (Roche Molecular Diagnostics
Products) that uses real-time polymerase chain reac-
tion (PCR).
Novartis claims a sensitivity of 100 copies for tissue
and live donor tissue samples. Roche claims a
sensitivity of 117–365 copies, depending on the level
of hemolysis of the sample. LABS, Inc. tested the
sensitivity of both assays and found them to be
adequate.
Both assays require a spiking of the sample with a
positive internal control. If the positive internal
control fails, there is a potential inhibitor. The
Novartis and Roche assays respond differently to
inhibitors.
‘‘It is possible that the internal control may not
work for West Nile assays,’’ Mr. Niedzinski said. He
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gave an example where the internal control did not
detect an inhibitor for both the TMA and PCR assays.
The WNV NAT screening assays do not have a
repeat or discriminatory test for reactive samples.
Therefore, these initial reactive, non-repeatable results
must be reported as reactive.
The Novartis and Roche assays are complex and
should be performed by experienced lab technologists.
Asked how many deceased tissue donors his lab
tests each year for WNV, Mr. Niedzinski said they
have done about 3,000 as of July 2010.
Karen Norman
Executive Director of Quality Assurance
RTI Biologics, Inc.
Karen Norman said her experience with WNV NAT
testing has been consistent with LABS, Inc.
RTI Biologics uses a semi-automated format for
small volume runs of 9–12 donors each. The kit is
based on an average of 55 tests per run, but the lab has
worked out an arrangement with the manufacturer
whereby it is billed only for the portions that are used.
WNV is temperature-sensitive, so the laboratory
temperature is well controlled, with back-up genera-
tors. A unidirectional workflow is in place to control
contamination. Invalid runs and specimens require
repeats, and 1.5 mL samples are recommended.
There is a short window to get the test done:
generally 24 h at 2–15C. If one centrifuges and
refrigerates the specimen, an additional 7 days can be
added for plasma. Two additional days can be added
for serum. If stored at -70C, 11 additional days are
allowed for both plasma and serum samples.
An individual specimen can be reactive, non-
reactive, or invalid. No further testing is done on
non-reactive specimens. Invalid specimens can be due
to inhibitory substances and these can be diluted and
re-run.
‘‘An invalid run is usually due to the calibrators not
meeting the acceptance criteria, and all specimens on
that run must be repeated,’’ Ms. Norman said.
RTI Biologics was part of the study to get the WNV
NAT kit on the market. It analyzed 4,569 samples, 16
of which gave a positive result. All 16 were negative,
or non-reactive, when re-tested by an independent lab.
Fifteen were non-reactive for IgM and IgG.
Testing continued after the end of the study in
December 2005. The invalid run rate in 2008 was 3%;
in 2009 it was 7.5%. An investigation found that the
2009 increase was tied to an individual technologist
who was subsequently retrained. The invalid specimen
rate for an individual test was 0.4% in 2008 and 1% in
2009. The reactive rate was 0.35% in 2008 and 0.39%




Following Dr. Lyle Petersen’s 2002 report on the risk
of transmission of WNV by transfusion, a cooperative
effort between screening assay manufacturers, blood
collection facilities and the FDA led to the implemen-
tation of screening of all U.S. volunteer blood
donations using mini-pool nucleic acid testing (MP-
NAT) under FDA approved INDs by July 2003. In
November 2003, recognition that transmissions of
WNV by blood transfusion had occurred led to
retrospective studies that found that MP-NAT detected
only 75% of the infected donations, said Dr. Maria
Rios. ‘‘The blood community re-evaluated the screen-
ing criteria and implemented individual donor NAT
(ID-NAT) during epidemic periods,’’ Dr. Rios said.
Screening of blood donors by MP-NAT and
implementation of ID-NAT during epidemic periods
from 2003 to 2009 prevented 3,000–9,000 potential
transmissions of WNV by transfusion. However,
despite selective implementation of ID-NAT, there
have been 11 recognized transmissions by transfusion
during those 7 years.
These occasional transmissions of WNV may be
related to the fact that infection often produces low-
level viremia leading to inconsistent test results. Viral
detection is challenging, as evidenced by the need
to implement an ID-NAT during certain periods to
replace MP-NAT in blood donors. In addition, the
positive predictive value of the tests varies with the
incidence.
The FDA is interested in getting data to demon-
strate test performance post licensure.
Testing human and non-human animal tissue
Robert Lanciotti, PhD
Chief, Diagnostic & Reference Library, Arbovirus
Disease Branch,
CDC, Fort Collins, Colorado
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The CDC looks for WNV in sentinel chicken flocks,
mosquito populations, and dead bird populations, said
Dr. Robert Lanciotti. It looks for the viral RNA in
collected mosquitoes or for the virus in amplifying
hosts; NAT is the test of choice.
Most tissue specimens received by the CDC are as a
result of neuroinvasive disease and serological testing
is the most valuable tool, Dr. Lanciotti said, noting that
combining with NAT helps to confirm infection.
Human infection is confirmed by the presence of
IgM in serum or cerebral spinal fluid (CSF). Serocon-
version is another indicator. To enhance diagnosis,
one can look for virus or viral RNA in serum CSF.
The CDC uses an IgM-ELISA test on beads, which
allows for multiplexing. A plaque reduction neutral-
ization test confirms specificity of infection.
‘‘The advantage of the microsphere assay is that we
can have unique bead sets—West Nile, St. Louis or
Eastern encephalitis—creating geographic panels, and
then take a single serum specimen and test it to all,’’
Dr. Lanciotti said.
Confounding the serological diagnosis is cross
reactivity among the flaviviruses. Japanese encepha-
litis can cause an indistinguishable reaction to WNV
and confirmation is required in a follow-up neutral-
ization test.
NAT tests are the most sensitive for detection of
WNV, followed by isolation of virus and detection of
antigen. The GenProbe and Roche tests have been
FDA-cleared for screening donor plasma.
Approximately 100 organs collected in autopsies
have been tested. Brain tissues are generally positive
for viral RNA. Real-time PCR can detect it nearly
100% of the time. West Nile RNA has not been
detected in organs collected from autopsies or from
urine specimens.
Discussion
A participant commented that a fair bit of serum
plasma—up to half a milliliter—is needed to ensure
that PCR is accurate. Dr. Lanciotti agreed that this is
probably the most important part of increasing sensi-
tivity in the NAT assay.
Another participant asked whether urine samples
were collected from living patients with neurologic
disease or from cadavers; Dr. Lanciotti said both
sources were used.
Asked whether particles can precipitate, Dr. Lanc-
iotti said they have not looked at that, but that they
routinely use a vortex mixer.
Regarding the autopsy samples, a participant asked
whether the negative organs were from patients who
had died from West Nile disease, or who had died from
another cause. Dr. Lanciotti said they were confirmed
West Nile cases; however, ‘‘We do not see the cause of
death report.’’ He said the next few speakers would
address the relevance of this information to current
issues in the tissue bank industry.
Tissue handling and processing studies
Carrie Hartill
Chief Scientific Officer and Vice President, Quality
Assurance & Regulatory Affairs
RTI Biologics, Inc.
For more than a decade, groups from around the world
have been identifying relevant and modeled viruses to
determine how tissue processing and handling prac-
tices may help to minimize and mitigate existing
viruses, said Carrie Hartill. As well, they have been
characterizing and allocating different types of patho-
gens, with the aim of creating better risk assessment.
WNV is a relatively low-resistant envelope virus,
and fragile to handle. Model viruses are chosen
because they tend to be hardier. Viruses are relatively
easy to kill and/or remove. As pathogen inactivation
technologies are developed, they are categorized
according to fragility.
‘‘In the big scheme of things, while we do need to
focus on viruses, they are not our biggest problem in
the tissue banking world,’’ Ms. Hartill said.
No single approach addresses all problems. Cold
storage and freezing can serve to inactivate some
organisms, but they are also preservation techniques
for others. Removal of blood and lipids is critical when
dealing with blood-borne pathogens. Storage at room
temperature for more than 30 days inhibits many
pathogens. Studies comparing traditional and new
processing and sterilization techniques are lacking.
‘‘Without having any visibility to all of these things,
the regulators are trying to develop policy about what
happens when the next pathogen comes along,’’ Ms.
Hartill said. ‘‘The industry has the responsibility to
give them the data.’’
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The World Health Organization (WHO) has taken
the approach of looking at transmission risk by cell
and tissue type. Infectivity studies are needed, Ms.
Hartill said, noting that the assays are in place.
When developing a pathogen inactivation study,
fluid exchange and dynamics are critical parts of
evaluating the mechanical aspects. As well, tissue
must not be harmed during techniques used in
processing, such as irradiation. There are few pub-
lished studies describing these processes.
Alyce Linthurst-Jones, PhD, RAC
Project Manager
LifeNet Health
Since the introduction of its Allowash XG cleaning
process in 1995, LifeNet has delivered more than two
million tissue grafts with no incidents of disease
transmission, said Dr. Alyce Linthurst-Jones. The
process begins with centrifugation to remove the
blood and bone marrow. Next, warmed hydrogen
peroxide is added to kill bacteria. Ultrasonication at
elevated temperatures with Allowash detergent
solution helps solubilize the bone marrow and
removes infectious agents. Finally, ultrasonication
with hydrogen peroxide cleans and removes agents.
‘‘We validated this process in the early 2000s,
ensuring that weight of bone to volume of reagents
used is consistent to support the validation that was
performed,’’ Dr. Linthurst-Jones said. ‘‘We terminally
irradiate, and part of making sure that our dose is valid
is making sure we have a consistently low bio-burden
going into the gamma radiation step. The disinfection
portion of Allowash is essential to maintaining the
validity of our radiation dose.’’
In the viral inactivation studies performed with
Allowash XG, more than three logs were killed for all
the model viruses. For WNV specifically, 10.4 logs
were achieved.
‘‘We were able to substantially clear and/or inac-
tivate enveloped, non-enveloped DNA, RNA, and




Mary Malarkey listed the following gaps and chal-
lenges in tissue processing, as seen from a regulator’s
perspective:
• Available data are lacking.
• Little active research is being conducted in
academia.
• Evaluation of irradiation processes for viruses of
interest is lacking.
• Validation and viral clearance studies are reviewed
on inspection rather than in the application
process.
• There has been lack of consideration of pre-
processing and/or sterility results for bacterial and
fungal agents (not related to viruses).
• There have been gaps in validation where partic-
ular steps have not been looked at. Lack of
validated processes or microbiological methods
has led to transmission.
• Changes in a process where validation has not been
done have led to transmission.
‘‘Even in the best possible world there is human
error, and this is always a concern,’’ Ms. Malarkey
said.
Discussion
Asked about dose parameters for irradiation, Scott
Brubaker offered that relevancy is ‘‘aimed at the
validation of your process and not to set a minimum
dose.’’ An AATB task force is developing a guidance
document to set minimum expectations for validation
processes, including culture methodologies, and using
examples for different tissues. ‘‘We have realized this
gap and we are on track to finish it,’’ he said.
Ms. Hartill added that the irradiation standards
were not promulgated with the idea of affecting
biological material. They were focused on traditional
bacterial reduction. Some organisms are highly sus-
ceptible to radiation, while others are highly resistant
and more susceptible to chemical treatment.
Roundtable discussion: scientific considerations
for tissue donors
‘‘What are the scientific considerations for tissue
donors and what research could be performed to
address those considerations?’’
During a panel discussion of the scientific consider-
ations for tissue donors, and research that could be
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performed to address those considerations, Dr. Fran-
cisca Agbanyo noted that Health Canada recommends
WNV testing for all tissue donors, but it is not
mandatory.
Dr. Harvey J. Stern said no evidence shows that
WNV is a sexually transmitted disease. ‘‘Even if
nucleic acids are present in reproductive tissues, is it
capable of being present in sperm and, if present,
would it survive processing?’’ He suggested that
animal experimentation could help discover the
answers to these questions.
A participant said, ‘‘We struggled with this issue
with living donors for organ transplantation,’’ and
asked whether the safest process would be to test those
individuals and defer them for a period of time, since it
is theoretically possible to procure the specimens 2 or
3 months after the PCR had been detected. This would
mean applying the principle of ‘‘first, do no harm’’ to
using tissue from a living person.
Dr. Stern said this might be possible, but would not
take into consideration the expense of testing. ‘‘I do
not think there is a problem testing in circumstances
where there is a real risk of transmission,’’ he said. ‘‘It
would be nice to know if this is an issue. I think the
jury is still out.
Dr. Bruce Bodner said that from the eye-banking
perspective, the FDA’s ongoing initiative regarding
evidence-based regulation is very important and
certainly welcome. While some believe the cornea to
be a privileged organ, he said, it is not known whether
it has any viral load, and if it does, whether it can
transmit the disease.
Dr. Celia Witten agreed that biovigilance is criti-
cally important to protect the public. The FDA does not
always want to wait until transmission is proven before
instituting a protective measure. It would be useful to
have studies on donor populations for WNV and other
diseases; it would also be helpful to have published
information on processing in a way that would enable
people to draw general conclusions over time.
Dr. Lyle Petersen emphasized the importance of
estimating the risk in tissue donors. ‘‘We can begin to
create models to estimate the risk and the benefits of
screening, and I would advocate for doing that,’’ he
said. ‘‘I also think we need good surveillance.’’
Dr. Greg Ray said continued research is needed to
look at processing methods directed at viral clearance.
As well, he said, ‘‘I am not sure the data indicate that
WNV is a serious concern for the tissue donation
population. There needs to be a well-defined risk
analysis model.’’
Dr. Michael Ison said it is now recognized that the
incidence of disease transmission is between 0.2 and
1% of all organ transplants. Many feel that there has
been no significant disease transmission (in tissue
transplantation) resulting in neuroinvasive disease,
‘‘but unless you show me some PCR data in those
patients (tissue recipients) who have fevers, I do not
believe that we can definitely say there has not been
any transmission (from tissue allografts).’’ He agreed
that intensive donor screening and (tissue) recipient
follow-up over a long period of time would be useful.
These issues apply to all emerging infections, said
Dr. David Gocke. He asked about the threshold of
evidence that must be accumulated ‘‘before we
embark on an elaborate, expensive, new test develop-
ment for WNV or any other disease.’’
We need to mobilize leadership in science and
prevention to effectively use our healthcare dollars,’’
said Dr. Jerry Holmberg. In reference to biovigilance
he noted that our beliefs dictate our behavior. For
example, ‘‘if you believe that there is no need for
surveillance and are not willing to put in place
mechanisms to look for problems, you are probably
going to continue in that frame of thinking and miss
opportunities for process improvement.’’ More sur-
veillance and data collection are needed, to determine
whether there is a problem, as well as how to approach
it.
Dr. Holmberg said the tissue community must step
up its public information efforts, which will in turn
spur research. Noting that there is ‘‘a void in respect to
tissue research support,’’ he asked participants to
consider how to stimulate manufacturing to respond to
this orphan community. Microarray technology, based
on genomic sequences, was referenced as an example
of new technology, which has potential for the tissue
and organ communities. He noted that health care
reform provided resources, especially for disease
prevention; the tissue community should go out and
seek opportunities for advancement. A participant
remarked, ‘‘We are good at coming up with national
policies, but there are more diseases that may affect
only small locales. We need to be flexible in our
thinking.’’ Another noted that an inexpensive way to
address protection would be to have regional blood
banks send emails to OPOs and eye banks to keep
everyone informed of current trends.
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A participant recommended collaborating with
local and state health departments to learn of endemic
diseases unique to specific locales, while another said,
‘‘We draw donors from all over the country. There is
no limitation on the amount of testing we would need
to do. It could not be done on a regional basis.’’
A participant challenged this, saying that if there is
a unique situation, triggered by unique history, ‘‘you
can consider what additional testing needs to happen.’’
Noting that many donors are already deferred because
of malaria, a participant said that in the blood bank
world, this is a larger issue. ‘‘I wish there were such a
thing as medical director discretion, but the exclu-
sionary rules are very broad.’’
Closing remarks
Scott A. Brubaker, CTBS
Chief Policy Officer
AATB
Much work remains to be done, said Scott Brubaker.
He described that the AATB would start working with
the FDA and CDC to develop study protocols to obtain
data that will characterize the virus as it relates to
donated conventional and reproductive tissues; he
noted that this is already being done with T. cruzi, with
much help from the CDC and input from FDA. We
have ongoing studies to find out if normal tissue
handling has a negative effect on that parasite. Related
studies should occur with WNV. He thanked partic-
ipants for attending, and closed the meeting.
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A Culex pipiens mosquito on a watermelon. This is a primary
vector of WNV in North America that bites both birds and
humans (anthropophagy)
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